Insights into Nanomedicine for Immunotherapeutics in Squamous Cell Carcinoma of the head and neck
Authors:
Open Access
- 1 January 2020
- journal article
- review article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 16 (14) , 2506-2517
Abstract
Immunotherapies such as immune checkpoint blockade benefit only a portion of patients with head and neck squamous cell carcinoma. The multidisciplinary field of nanomedicine is emerging as a promising strategy to achieve maximal anti-tumor effect in cancer immunotherapy and to turn non-responders into responders. Various methods have been developed to deliver therapeutic agents that can overcome bio-barriers, improve therapeutic delivery into the tumor and lymphoid tissues and reduce adverse effects in normal tissues. Additional modification strategies also have been employed to improve targeting and boost cytotoxic T cell-based immune responses. Here, we review the state-of-the-art use of nanotechnologies in the laboratory, in advanced preclinical phases as well as those running through clinical trials assessing their advantages and challenges.Keywords
This publication has 114 references indexed in Scilit:
- Anticancer and immunostimulatory role of encapsulated tumor antigen containing cobalt oxide nanoparticlesJBIC Journal of Biological Inorganic Chemistry, 2013
- Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor ImmunityCancer Research, 2013
- Optimization of Stability, Encapsulation, Release, and Cross-Priming of Tumor Antigen-Containing PLGA NanoparticlesPharmaceutical Research, 2012
- A novel self-assembled nanoparticle vaccine with HIV-1 Tat49-57/HPV16 E749-57 fusion peptide and GM-CSF DNA elicits potent and prolonged CD8+ T cell-dependent anti-tumor immunity in miceVaccine, 2012
- Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular TargetingScience Translational Medicine, 2011
- T Cell‐Tumor Interaction Directs the Development of Immunotherapies in Head and Neck CancerJournal of Immunology Research, 2010
- Combination Nonviral Murine Interleukin 2 and Interleukin 12 Gene Therapy and Radiotherapy for Head and Neck Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2005
- Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma AntigenClinical Cancer Research, 2004
- Immunostimulation Mechanism of LPD Nanoparticle as a Vaccine CarrierMolecular Pharmaceutics, 2004
- A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCCAuris Nasus Larynx, 2004